Host Immunometabolic Modulators for Severe Febrile Syndromes

Abstract

Severe febrile syndromes, including sepsis, malaria, and viral hemorrhagic fevers, are associated with substantial morbidity and mortality, particularly in critically ill patients. Traditional management has focused primarily on antimicrobial therapies and supportive care, but emerging evidence highlights the pivotal role of host immunometabolic pathways in determining disease outcome. This review synthesizes current understanding of immunometabolic dysregulation in severe febrile syndromes and evaluates the therapeutic potential of targeting these pathways with immunometabolic modulators. We discuss epidemiological trends, key pathophysiological mechanisms, clinical presentation, diagnostic approaches, and established as well as emerging immunometabolic interventions. The review concludes with guideline-based recommendations and future directions for integrating immunometabolic modulators into clinical practice for improved patient outcomes.

Introduction

Severe febrile syndromes encompass a spectrum of life-threatening conditions characterized by persistent high fever and systemic inflammation, such as sepsis, severe malaria, leptospirosis, and viral hemorrhagic fevers. Despite advances in supportive and antimicrobial therapy, mortality rates remain high, reflecting the complex interplay between pathogen factors and host immune responses. Increasingly, research has focused on the immunometabolic alterations that occur during these syndromes and their contribution to disease progression. Immunometabolic modulators—agents that target the intersection of immune signaling and metabolic pathways—offer a novel therapeutic avenue that may attenuate excessive inflammation while preserving host defenses. This review aims to provide clinicians and researchers with an updated synthesis of the evidence base for immunometabolic modulation in severe febrile syndromes, emphasizing clinically relevant mechanisms and emerging therapeutic strategies.

Epidemiology / Disease Burden

Severe febrile syndromes represent a significant global health burden, especially in low- and middle-income countries. Sepsis accounts for an estimated 11 million deaths annually worldwide, with a disproportionate impact on children, the elderly, and immunocompromised individuals. Malaria, particularly caused by Plasmodium falciparum, results in over 400,000 deaths each year, primarily in sub-Saharan Africa. Viral hemorrhagic fevers, such as Ebola and dengue, periodically cause localized outbreaks with high case-fatality rates. The rising incidence of antimicrobial resistance further complicates management and underscores the need for host-directed therapies. Epidemiological studies indicate that outcomes in severe febrile syndromes are influenced not only by pathogen characteristics but also by the host's genetic, metabolic, and immunological landscape, positioning immunometabolic modulation as a promising therapeutic target.

Pathophysiology

Host immunometabolic dysregulation is a central feature of severe febrile syndromes. Upon pathogen recognition, immune cells rapidly shift from oxidative phosphorylation to aerobic glycolysis—a process termed the "Warburg effect"—to meet energy demands for effective defense. However, sustained or dysregulated metabolic reprogramming can drive hyperinflammation, tissue injury, and organ dysfunction. Key pathways implicated include the mTOR, HIF-1α, and AMPK signaling cascades, which regulate cellular metabolism, cytokine production, and immune cell differentiation. Mitochondrial dysfunction and impaired fatty acid oxidation further exacerbate metabolic stress. In sepsis, for example, excessive glycolysis is associated with increased lactate production, immunoparalysis, and poor prognosis. Targeting these metabolic checkpoints with immunometabolic modulators may restore immune homeostasis and improve clinical outcomes.

Risk Factors

Several host and environmental factors predispose individuals to immunometabolic derangements during severe febrile syndromes. Advanced age, obesity, diabetes, malnutrition, and chronic comorbidities are strongly associated with impaired metabolic flexibility and heightened inflammatory responses. Genetic polymorphisms affecting key metabolic enzymes or immune receptors can also modulate susceptibility. Additionally, environmental factors—such as exposure to high pathogen loads, delayed treatment, or concomitant infections—can amplify metabolic and immune dysregulation. Recognizing these risk factors is critical for identifying patients most likely to benefit from immunometabolic modulation and for implementing personalized therapeutic strategies.

Clinical Features

Severe febrile syndromes typically present with high-grade fever, chills, malaise, and rapidly progressive systemic symptoms. Clinical hallmarks may include hypotension, tachycardia, tachypnea, and evidence of end-organ dysfunction such as acute kidney injury, hepatic impairment, or acute respiratory distress syndrome. In malaria, additional features include hemolytic anemia, hypoglycemia, and cerebral involvement. Viral hemorrhagic fevers often manifest with mucocutaneous bleeding, shock, and coagulopathy. The clinical heterogeneity of these syndromes reflects the underlying immunometabolic disturbances and the balance between pro-inflammatory and compensatory anti-inflammatory responses.

Diagnosis

Diagnosis of severe febrile syndromes requires a combination of clinical assessment, laboratory investigations, and, where available, pathogen-specific testing. Biomarkers of immunometabolic dysfunction, such as elevated lactate, procalcitonin, cytokine panels (e.g., IL-6, TNF-α), and metabolic intermediates, can aid in risk stratification and prognostication. Imaging modalities and organ function tests further assist in assessing disease severity. Recent advances in metabolomics and transcriptomics hold promise for more precise identification of immunometabolic phenotypes, enabling tailored therapeutic interventions.

Treatment & Management

Conventional management of severe febrile syndromes centers on prompt antimicrobial therapy, hemodynamic support, and organ function optimization. However, adjunctive immunometabolic modulation is gaining traction as a strategy to improve outcomes. Agents such as metformin, statins, and thiamine have demonstrated immunomodulatory effects by influencing metabolic pathways, dampening excessive inflammation, and preserving mitochondrial function. For example, metformin activates AMPK and promotes autophagy, reducing cytokine storm severity in sepsis models. Statins modulate cholesterol metabolism and exhibit anti-inflammatory effects. Thiamine supplementation corrects metabolic acidosis and may reduce organ dysfunction. The timing, selection, and dosing of these agents require careful consideration to balance immune activation and suppression.

Recent Advances / Emerging Therapies

Recent research has identified several novel immunometabolic modulators with therapeutic potential in severe febrile syndromes. Inhibitors of glycolytic enzymes, HIF-1α antagonists, and agents targeting mitochondrial biogenesis are under investigation in preclinical and early-phase clinical studies. Beta-hydroxybutyrate, a ketone body, has shown promise in restoring mitochondrial function and reducing systemic inflammation. Immune checkpoint modulators, such as PD-1/PD-L1 inhibitors, may reverse immunoparalysis in late-stage sepsis. Nanoparticle-based delivery systems are being explored to enhance the specificity and bioavailability of immunometabolic agents. Ongoing clinical trials are evaluating the safety and efficacy of these interventions, with early results suggesting potential for improved survival and reduced organ failure.

Guideline Recommendations

Current international guidelines, including those from the Surviving Sepsis Campaign and the World Health Organization, emphasize early recognition and supportive management of severe febrile syndromes. While immunometabolic modulation is not yet included as standard of care, expert consensus recognizes its potential, particularly in high-risk patient subsets. Guidelines recommend consideration of adjunctive therapies such as thiamine in refractory septic shock and advocate for ongoing participation in clinical trials evaluating new immunometabolic agents. Multidisciplinary collaboration and individualized patient assessment are essential to optimize outcomes while minimizing adverse effects.

Conclusion

Host immunometabolic modulators represent a promising frontier in the management of severe febrile syndromes, addressing critical gaps left by pathogen-directed therapies alone. Integrating mechanistic understanding of immunometabolic dysregulation with clinical application may enable more precise, personalized, and effective interventions. Continued research, rigorous clinical trials, and updated guideline development are needed to clarify the role of immunometabolic modulators in routine practice and to realize their full potential in improving patient outcomes in severe febrile syndromes.